CS 526
Alternative Names: AKU 517; R 105266Latest Information Update: 22 Jan 2008
At a glance
- Originator Daiichi Sankyo Inc; Ube Industries
- Developer Daiichi Sankyo Inc; Novartis; Ube Industries
- Class Antiulcers; Gastrokinetics
- Mechanism of Action Potassium-competitive acid blockers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Gastro-oesophageal reflux; Peptic ulcer
Most Recent Events
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
- 10 Oct 2003 Phase-I clinical trials in Gastro-oesophageal reflux in USA (PO)
- 08 Oct 2003 Sankyo and Novartis have entered into an agreement to co-promote and co-develop CS 526 in the US and Europe for Gastro-oesophageal reflux disease and peptic ulcers